启动连续性肾脏替代治疗后血小板下降与继发感染率增加相关
该回顾性队列利用Mayo Clinic CRRT数据库,纳入ICU存活且CRRT<30天的成人797例,其中253例启动时血小板<100×10³/µL。主要预测变量为CRRT启动后血小板较前下降>40% vs ≤40%,主要终点为ICU转出后感染。提示CRRT启动后血小板大幅下降可能提示继发感染风险增高,需进一步研究。
要点
- 该关联来自回顾性队列的多变量及倾向校正分析,不能推断因果,需前瞻性验证。
- 次要终点(ICU转出后感染性休克、ICU转出后死亡)的原文具体结果未在摘要中给出。
适用人群与场景
- 成人ICU患者,存活至ICU转出且CRRT持续时间<30天者纳入分析。
- 亚组分析纳入CRRT启动时血小板<100×10³/µL的血小板减少患者。
- 排除人群、院前场景及非ICU场景原文未提及。
诊断标准与关键阈值
- 主要预测变量:CRRT启动后血小板较启动前下降>40% vs ≤40%,原文另分析多个切点但未列出具体界值。
- 血小板减少定义:CRRT启动时血小板<100×10³/µL。
- 主要终点:ICU转出后感染;次要终点:ICU转出后感染性休克、ICU转出后死亡。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- CRRT启动后血小板较基线下降>40%,尤其启动时已存在血小板<100×10³/µL者,需警惕ICU转出后继发感染风险增加。
- 原文未给出针对该红旗征的具体处理措施。
研究设计与关键结果
- 研究类型:单中心(Mayo Clinic Rochester)回顾性队列分析,样本量797例,其中253例CRRT启动时血小板<100×10³/µL。
- 次要终点(ICU转出后感染性休克、ICU转出后死亡)及不良事件的具体结果原文摘要未给出。
- 原文另分析多个血小板下降切点,但摘要未列出各切点结果。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 证据等级或推荐强度:原文未提及。
- 局限:回顾性设计、单中心、仅纳入存活至ICU转出且CRRT<30天者,可能存在选择偏倚与残余混杂;原文结论指出需进一步研究评估CRRT及血小板丢失对后续感染风险的影响。
对床旁实践的改变
- 对CRRT启动后血小板较基线下降>40%的ICU患者,尤其启动时血小板<100×10³/µL者,可在ICU转出后加强感染监测。
- 该关联为回顾性观察结果,不能据此改变CRRT启动或抗凝策略,原文未给出干预建议。
- 不适用于未存活至ICU转出或CRRT≥30天的患者(原文未纳入)。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Thrombocytopenia is common in critically ill patients treated with continuous renal replacement therapy and decreases in platelets following continuous renal replacement therapy initiation have been associated with increased mortality. Platelets play a role in innate and adaptive immunity, making it plausible that decreases in platelets following continuous renal replacement therapy initiation predispose patients to development of infection. Our objective was to determine if greater decreases in platelets following continuous renal replacement therapy correlate with increased rates of secondary infection.
DESIGN: Retrospectivecohort analysis.
SETTING: This study uses a continuous renal replacement therapy database from Mayo Clinic (Rochester, MN), a tertiary academic center.
PARTICIPANTS: Adult patients who survived until ICU discharge and were on continuous renal replacement therapy for less than 30 days were included. A subgroup analysis was also performed in patients with thrombocytopenia (platelets < 100 × 103/µL) at continuous renal replacement therapy initiation.
MEASUREMENTS AND MAIN RESULTS: The primary predictor variable was a decrease in platelets from precontinuous renal replacement therapy levels of greater than 40% or less than or equal to 40%, although multiple cut points were analyzed. The primary outcome was infection after ICU discharge, and secondary endpoints included post-ICU septic shock and post-ICU mortality. Univariable, multivariable, and propensity-adjusted analyses were used to determine associations between the predictor variable and the outcomes.
RESULTS: Among 797 eligible patients, 253 had thrombocytopenia at continuous renal replacement therapy initiation. A greater than 40% decrease in platelets after continuous renal replacement therapy initiation was associated in the multivariable-adjusted models with increased odds of post-ICU infection in the full cohort (odds ratio, 1.49; CI, 1.02-2.16) and in the thrombocytopenia cohort (odds ratio, 2.63; CI, 1.35-5.15) cohorts.
CONCLUSIONS: Platelet count drop by greater than 40% following continuous renal replacement therapy initiation is associated with an increased risk of secondary infection, particularly in patients with thrombocytopenia at the time of continuous renal replacement therapy initiation. Further research is needed to evaluate the impact of both continuous renal replacement therapy and platelet loss on subsequent infection risk.
参考来源
- Griffin BR, Wu C, O'Horo JC, et al. The Association of Platelet Decrease Following Continuous Renal Replacement Therapy Initiation and Increased Rates of Secondary Infections. Crit Care Med. 2021. PMID: 33372743. doi:10.1097/CCM.0000000000004763
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。